Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

December 4, 2017

Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network

November 27, 2017

Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test

November 13, 2017

Exosome Diagnostics and Leading Academic Cancer Center Demonstrate Superior Liquid Biopsy Performance

October 11, 2017

Exosome Diagnostics to Present a Novel Atlas of Exosomal mRNA and Long non-coding RNA Across Biofluids at American Society of Exosomes and Microvesicles Annual Meeting

September 19, 2017

Exosome Diagnostics and Chesapeake Urology Partner to Evaluate Clinical Value of ExoDx® Prostate(IntelliScore) in First Study Under Novel Evidence Development Collaboration

August 24, 2017

CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic Tests

August 9, 2017

Exosome Diagnostics Launches the MedOncAlyzer™ Pan-Cancer Panel

August 3, 2017

Exosome Diagnostics Achieves ISO 13485 Certification

August 1, 2017

Exosome Diagnostics Announces New World Headquarters and Laboratory in Waltham, MA

July 24, 2017

Exosome Diagnostics Completes $30 Million Series C Financing

June 22, 2017

Exosome Diagnostics Presents Breakthrough Liquid Biopsy Technologies at BIO International Convention

May 31, 2017

Exosome Diagnostics Will Demonstrate the “Shahky” Point of Care Protein Detection Instrument at American Society for Clinical Oncology

UPCOMING EVENTS

View more News and Events

Now available to Heathcare Providers for Clinical Use: The Industry’s First Exosome-Based Liquid Biopsy Tests

Order Here

The Industry’s First RNA-Based Liquid Biopsies

We are bringing the first exosome-based diagnostics to market. Learn more about our Laboratory Developed Tests, which will be analyzed in our CLIA-certified laboratory: